Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.
Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Grove W, Macdonald K, Gulyas S, Clark M, Dasse KD. Richards DA, et al. Among authors: rosemurgy a. Ann Oncol. 2006 Jul;17(7):1096-102. doi: 10.1093/annonc/mdl081. Epub 2006 Apr 26. Ann Oncol. 2006. PMID: 16641168 Free article. Clinical Trial.
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N. Senzer N, et al. Among authors: rosemurgy a. J Clin Oncol. 2004 Feb 15;22(4):592-601. doi: 10.1200/JCO.2004.01.227. Epub 2004 Jan 15. J Clin Oncol. 2004. PMID: 14726502 Clinical Trial.
Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.
Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA. Herman JM, et al. Among authors: rosemurgy a. J Clin Oncol. 2013 Mar 1;31(7):886-94. doi: 10.1200/JCO.2012.44.7516. Epub 2013 Jan 22. J Clin Oncol. 2013. PMID: 23341531 Free PMC article. Clinical Trial.
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.
Evans TRJ, Van Cutsem E, Moore MJ, Bazin IS, Rosemurgy A, Bodoky G, Deplanque G, Harrison M, Melichar B, Pezet D, Elekes A, Rock E, Lin C, Strauss L, O'Dwyer PJ. Evans TRJ, et al. Among authors: rosemurgy a. Ann Oncol. 2017 Feb 1;28(2):354-361. doi: 10.1093/annonc/mdw607. Ann Oncol. 2017. PMID: 27998964 Free article. Clinical Trial.
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer.
Muscarella P, Bekaii-Saab T, McIntyre K, Rosemurgy A, Ross SB, Richards DA, Fisher WE, Flynn PJ, Mattson A, Coeshott C, Roder H, Roder J, Harrell FE, Cohn A, Rodell TC, Apelian D. Muscarella P, et al. Among authors: rosemurgy a. J Pancreat Cancer. 2021 Mar 23;7(1):8-19. doi: 10.1089/pancan.2020.0021. eCollection 2021. J Pancreat Cancer. 2021. PMID: 33786412 Free PMC article.
32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: a randomized trial.
Rosemurgy A, Luzardo G, Cooper J, Bowers C, Zervos E, Bloomston M, Al-Saadi S, Carroll R, Chheda H, Carey L, Goldin S, Grundy S, Kudryk B, Zwiebel B, Black T, Briggs J, Chervenick P. Rosemurgy A, et al. J Gastrointest Surg. 2008 Apr;12(4):682-8. doi: 10.1007/s11605-007-0430-6. Epub 2008 Feb 12. J Gastrointest Surg. 2008. PMID: 18266048 Clinical Trial.
385 results